Back to Browse Journals » Breast Cancer: Targets and Therapy » Volume 3

Triple-negative (ER, PgR, HER-2/neu) breast cancer in Indian women

Authors Vinayak W Patil, Rajeev Singhai, Amit V Patil, et al

Published 16 March 2011 Volume 2011:3 Pages 9—19


Review by Single-blind

Peer reviewer comments 2

This paper has been retracted.
Vinayak W Patil1, Rajeev Singhai1, Amit V Patil2, Prakash D Gurav2
1Department of Biochemistry, Grant Medical College and Sir JJ Group of Hospitals, Mumbai, India; 2Department of Surgery, Government Medical College, Miraj, India

Abstract: The aim of our study was to analyze triple-negative (TN) breast cancer, which is defined as being negative for the estrogen receptor (ER), the progesterone receptor (PgR), and the human epidermal growth factor receptor 2 (HER-2/neu) and which represents a subset of breast cancer with different biologic behavior. We investigated the clinicopathological characteristics and prognostic indicators of lymph node-negative TN breast cancer. Medical records were reviewed from patients with node-negative breast cancer who underwent curative surgery at Grant Medical College and Sir JJ Group of Hospitals, Mumbai, India, from May 2007 to October 2010. Clinicopathological variables and clinical outcomes were evaluated. Among 683 patients included, 136 had TN breast cancer and 529 had non-TN breast cancer. TN breast cancer correlated with younger age (<35 years, P = 0.003) and a higher histopathologic and nuclear grade (P < 0.001). It also correlated with a molecular profile associated with biological aggressiveness: negative for Bcl-2 expression (P < 0.001), positive for the epidermal growth factor receptor (P = 0.003), and a high level of p53 (P < 0.001) and Ki-67 expression (P < 0.00). The relapse rates during the follow-up period (median 56.8 months) were 14.7% for TN breast cancer and 6.6% for non-TN breast cancer (P = 0.004). Relapse-free survival (RFS) was significantly shorter among patients with TN breast cancer compared with those with non-TN breast cancer: 3.5-year RFS rate 85.5% versus 94.2%, respectively; P = 0.001. On multivariate analysis, young age, close resection margin, and triple negativity were independent predictors of shorter RFS. TN breast cancer had a higher relapse rate and more aggressive clinicopathological characteristics than non-TN in node-negative breast cancer. Thus, TN breast cancer should be integrated into risk factor analysis for node-negative breast cancer.

Keywords: TN breast cancer, hormone receptors, ER, PgR, HER-2/neu, Ki-67

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] View Full Text [HTML] 


Other articles by this author:

The p53 breast cancer tissue biomarker in Indian women

Patil V, Tayade M, Pingale S, Dalvi S, Rajekar R, Deshmukh H, Patil S, Singhai R

Breast Cancer: Targets and Therapy 2011, 3:71-78

Published Date: 11 August 2011

Estrogen receptor (ER) and progesterone receptor (PgR) in breast cancer of Indian women

Patil AV, Bhamre RS, Singhai R, Tayade MB, Patil VW

Breast Cancer: Targets and Therapy 2011, 3:27-33

Published Date: 19 April 2011

Cancer biomarker HER-2/neu in breast cancer in Indian women

Singhai R, Patil VW, Patil AV

Breast Cancer: Targets and Therapy 2011, 3:21-26

Published Date: 29 March 2011

Readers of this article also read:

Oral treatment with the herbal formula B307 alleviates cardiac toxicity in doxorubicin-treated mice via suppressing oxidative stress, inflammation, and apoptosis

Lien CY, Chuang TY, Hsu CH, Lin CL, Wang SE, Sheu SJ, Chien CT, Wu CH

OncoTargets and Therapy 2015, 8:1193-1210

Published Date: 26 May 2015

Dry powder cationic lipopolymeric nanomicelle inhalation for targeted delivery of antitubercular drug to alveolar macrophage

Vadakkan MV, Annapoorna K, Sivakumar KC, Mundayoor S, Kumar GSV

International Journal of Nanomedicine 2013, 8:2871-2885

Published Date: 7 August 2013


Singhai R

Breast Cancer: Targets and Therapy 2012, 4:33-34

Published Date: 8 March 2012

Role of trastuzumab in the management of HER2-positive metastatic breast cancer

Andrea Milani, Filippo Montemurro, Luisa Gioeni, et al

Breast Cancer: Targets and Therapy 2010, 2:93-109

Published Date: 24 November 2010

Self-assessed health of young-to-middle-aged adults in an English-speaking Caribbean nation

Paul A Bourne, Neva South-Bourne

Patient Related Outcome Measures 2010, 1:127-140

Published Date: 28 September 2010

Health literacy and health seeking behavior among older men in a middle-income nation

Paul A Bourne, Chloe Morris, Christopher AD Charles, et al

Patient Related Outcome Measures 2010, 1:39-49

Published Date: 26 May 2010

p130Cas substrate domain signaling promotes migration, invasion, and survival of estrogen receptor-negative breast cancer cells

Anna C Cunningham-Edmondson, Steven K Hanks

Breast Cancer: Targets and Therapy 2009, 1:39-52

Published Date: 7 December 2009

Daunorubicin-loaded magnetic nanoparticles of Fe3O4 overcome multidrug resistance and induce apoptosis of K562-n/VCR cells in vivo

Bao-an Chen, Bin-bin Lai, Jian Cheng, et al

International Journal of Nanomedicine 2009, 4:201-208

Published Date: 23 September 2009

Editorial: Metabolic syndrome: sign of things to come ||FREE PAPER||

Reza Tabrizchi

Vascular Health and Risk Management 2006, 2:193-194

Published Date: 15 September 2006